VTv Stock: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst (NASDAQ:VTVT)

vTv Therapeutics Inc. ( VTVT ) is a late clinical-stage biopharmaceutical company that focuses on the development of therapies for Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and other chronic conditions. Its flagship candidate is Cadisegliatin (TTP399), an oral glucokinase activator beingMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, A ...